Substances and appliances
A variety of capabilities
For years, Bracco has invested heavily in research and development as well as pre-clinical and clinical development of imaging agents for in vivo imaging. An important milestone is Iopamidol, the first molecule discovered and developed by Bracco in 1981. Iopamidol was followed by other imaging agents created, developed, and marketed by Bracco – for use in X-ray, MRI, ultrasound, and nuclear medicine screenings and examinations.
In more recent years, we have acquired valuable competencies and research skills in imaging-related sectors such as automatic delivery systems and medical software for quantitative analysis of images.Our product portfolio
A wealth of innovation
Our proud scientific heritage has left us with a wealth of innovation that we've accumulated over the years. Intellectual property (IP) is one of the key assets for the development of research and innovation. The continuous interaction between the IP function and R&D allows the Group to follow the evolution of projects from the initial phase, identify possible innovations in different areas and evaluate the most suitable tools for their protection (for example patenting).